CTOs on the Move


 
The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting Platform to create a portfolio of NDCs designed to selectively attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations. Our first platform-generated candidate, CRLX101, is in multiple clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy. Our second platform-generated candidate, CRLX301, is in a Phase 1/2a clinical trial.
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million
  • www.ceruleanrx.com
  • 840 Memorial Drive 5th Floor
    Cambridge, MA USA 02139
  • Phone: 617.551.9600

Executives

Name Title Contact Details

Similar Companies

Intellia Therapeutics

Intellia Therapeutics is a leading genome editing company whose mission is to develop potentially curative gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases. We are focused on the development of proprietary therapeutics using a recently developed biological tool known as the CRISPR/Cas9 system. The promise of the CRISPR/Cas9 system is the driving force behind the creation of Intellia. Our founders have a shared belief that the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. This technology offers the potential for us to develop curative therapeutic options for patients with chronic diseases by addressing the underlying cause of the disease. It can bring new hope and cures to people who now have nowhere to turn for help. Our combination of deep scientific expertise and clinical development experience, along with our leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Intellia has the right people, assets and ambitious vision needed to take full advantage of the CRISPR/Cas9 technology`s attributes – high potency, specificity, simplicity of use, broad applicability, and multifunctional programmability – and accelerate the advancement of curative products into the clinic.

Vitalcor

Vitalcor is a Westmont, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RDMD

RDMD`s mission is to empower patients and communities to accelerate the development of treatments for rare diseases of all kinds.

BioVex Inc

BioVex Inc is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Athenix

Athenix Corp. is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.